Medications for Mesothelioma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mesothelioma.
Found 4 Approved Drugs for Mesothelioma
Pemetrexed
Brand Names
Alimta, Pemrydi Rtu, AXTLE, Pemfexy
Pemetrexed
Brand Names
Alimta, Pemrydi Rtu, AXTLE, Pemfexy
Form: Injection, Solution
Method of administration: Intravenous, Intraventricular
FDA approval date: February 04, 2004
Classification: Folate Analog Metabolic Inhibitor
Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer NSCLC, with no EGFR or ALK genomic tumor aberrations.
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Endoglycosidase
OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
Yervoy
Generic Name
Ipilimumab
Yervoy
Generic Name
Ipilimumab
Form: Injection
Method of administration: Intravenous
FDA approval date: March 25, 2011
Classification: CTLA-4-directed Blocking Antibody
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
Keytruda
Generic Name
Pembrolizumab
Keytruda
Generic Name
Pembrolizumab
Form: Injection
Method of administration: Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances